机构:[1]Cancer Center, Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[2]Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A-STAR), Singapore 138673, Singapore.[3]Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[4]Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[5]Cancer Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[6]Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore.[7]Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.
China Postdoctoral Science Foundation (No. 2021M702346),
the Post-Doctor Research Project, West China
Hospital, Sichuan University (No. 2021HXBH092), the
Fundamental Research Funds for the Central
Universities (No. 2023SCU12051), Sichuan Science
and Technology Program (2023YFS0003), National
Key Research and Development Program of China
(2024YFA1306400), the Agency for Science,
Technology and Research (A∗STAR) under its
Industry Alignment Fund-Pre-Positioning Program
(H23J2a0095) and Competitive Research Programme(CRP29-2022-0032).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|1 区医学
小类|1 区医学:研究与实验
最新[2025]版:
大类|1 区医学
小类|1 区医学:研究与实验
第一作者:
第一作者机构:[1]Cancer Center, Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.[2]Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A-STAR), Singapore 138673, Singapore.
共同第一作者:
通讯作者:
通讯机构:[2]Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A-STAR), Singapore 138673, Singapore.[3]Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.[5]Cancer Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China.[6]Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore.[7]Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.
推荐引用方式(GB/T 7714):
Qin Diyuan,Lei Yanna,Shu Pei,et al.Supercharging CAR-T cells through transcriptional and epigenetic armoring[J].Theranostics.2025,15(8):3345-3367.doi:10.7150/thno.107908.
APA:
Qin Diyuan,Lei Yanna,Shu Pei,Zhang Yugu,Loh Yuin-Han...&Li Qijing.(2025).Supercharging CAR-T cells through transcriptional and epigenetic armoring.Theranostics,15,(8)
MLA:
Qin Diyuan,et al."Supercharging CAR-T cells through transcriptional and epigenetic armoring".Theranostics 15..8(2025):3345-3367